3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
durvalumab
3
selpercatinib
2
palbociclib
2
Gonadotropin-Releasing Hormone
2
Cisplatin
2
Anastrozole
2
AZD9833
2
ribociclib
1
pembrolizumab
1
gallium 68 PSMA-11
1
ceralasertib
1
camrelizumab
1
anlotinib
1
abemaciclib
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Pemetrexed
1
Paclitaxel
1
Nimorazole
1
Letrozole
1
Immunotherapy
1
Fulvestrant
1
CP protocol
1
Aspirin
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms by Site
×
AZD9833
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled